Sarcopenia – The search for emerging biomarkers

[1]  E. Papathanassoglou,et al.  May BDNF Be Implicated in the Exercise-Mediated Regulation of Inflammation? Critical Review and Synthesis of Evidence , 2015, Biological research for nursing.

[2]  S. Kersten,et al.  The search for exercise factors in humans , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  T. Spector,et al.  Genomics and metabolomics of muscular mass in a community-based sample of UK females , 2015, European Journal of Human Genetics.

[4]  A. Crujeiras,et al.  Irisin: ‘fat’ or artefact , 2015, Clinical endocrinology.

[5]  F. Huang,et al.  Metformin promotes irisin release from murine skeletal muscle independently of AMP‐activated protein kinase activation , 2015, Acta physiologica.

[6]  W. Aoi,et al.  Current understanding of sarcopenia: possible candidates modulating muscle mass , 2015, Pflügers Archiv - European Journal of Physiology.

[7]  Sarah M. Greising,et al.  Ageing and neurotrophic signalling effects on diaphragm neuromuscular function , 2015, The Journal of physiology.

[8]  C. Franceschi,et al.  Differential expression of perilipin 2 and 5 in human skeletal muscle during aging and their association with atrophy-related genes , 2015, Biogerontology.

[9]  Jeremy R. Townsend,et al.  C‐terminal agrin fragment is inversely related to neuromuscular fatigue in older men , 2015, Muscle & nerve.

[10]  M. Polkey,et al.  Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs , 2014, Thorax.

[11]  B. Tseng,et al.  Treatment of sporadic inclusion body myositis with bimagrumab , 2014, Neurology.

[12]  F. Marini,et al.  Serum levels of C-terminal agrin fragment (CAF) are associated with sarcopenia in older hip fractured patients , 2014, Experimental Gerontology.

[13]  R. Enoka,et al.  Tirasemtiv amplifies skeletal muscle response to nerve activation in humans , 2014, Muscle & nerve.

[14]  I. Bautmans,et al.  Identification and treatment of older persons with sarcopenia , 2014, The aging male : the official journal of the International Society for the Study of the Aging Male.

[15]  T. Bertsch,et al.  Sarcopenic obesity: molecular clues to a better understanding of its pathogenesis? , 2014, Biogerontology.

[16]  S. Heymsfield,et al.  Lean Tissue Imaging , 2014, JPEN. Journal of parenteral and enteral nutrition.

[17]  S. Anker,et al.  Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014 , 2014, Journal of cachexia, sarcopenia and muscle.

[18]  G. Biolo,et al.  Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. , 2014, Clinical nutrition.

[19]  Jeffrey R Stout,et al.  Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS) , 2014, Age and ageing.

[20]  S. Saetung,et al.  Circulating Sclerostin and Irisin Are Related and Interact with Gender to Influence Adiposity in Adults with Prediabetes , 2014, International journal of endocrinology.

[21]  S. Bartels,et al.  Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III , 2014, European Journal of Clinical Nutrition.

[22]  Marco Paoloni,et al.  Clinical definition of sarcopenia. , 2014, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[23]  M. Sandri,et al.  TGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease , 2014, Trends in Endocrinology & Metabolism.

[24]  Baoji Xu,et al.  BDNF signaling and survival of striatal neurons , 2014, Front. Cell. Neurosci..

[25]  A. Scholz,et al.  Genome-wide QTL mapping of nine body composition and bone mineral density traits in pigs , 2014, Genetics Selection Evolution.

[26]  Luigi Ferrucci,et al.  The Neuromuscular Junction: Aging at the Crossroad between Nerves and Muscle , 2014, Front. Aging Neurosci..

[27]  D. R. Alchin.  Sarcopenia: describing rather than defining a condition , 2014, Journal of cachexia, sarcopenia and muscle.

[28]  B. Picard,et al.  Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways , 2014, Cellular and Molecular Life Sciences.

[29]  G. Livshits,et al.  Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption–formation cycles? , 2014, Osteoporosis International.

[30]  N. Ishiguro,et al.  Managing sarcopenia and its related-fractures to improve quality of life in geriatric populations. , 2014, Aging and disease.

[31]  M. Cesari,et al.  Sarcopenia and Physical Frailty: Two Sides of the Same Coin , 2014, Front. Aging Neurosci..

[32]  M. Hirafuji,et al.  Skeletal muscle is an endocrine organ. , 2014, Journal of pharmacological sciences.

[33]  A. McArdle,et al.  Mechanisms of skeletal muscle ageing; avenues for therapeutic intervention. , 2014, Current opinion in pharmacology.

[34]  Y. Ouchi,et al.  Large-scale analysis reveals a functional single-nucleotide polymorphism in the 5′-flanking region of PRDM16 gene associated with lean body mass , 2014, Aging cell.

[35]  Rüdiger Rudolf,et al.  Degeneration of Neuromuscular Junction in Age and Dystrophy , 2014, Front. Aging Neurosci..

[36]  Rosaly Correa-de-Araujo,et al.  Skeletal muscle function deficit: a new terminology to embrace the evolving concepts of sarcopenia and age-related muscle dysfunction. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[37]  G. Lippi,et al.  Biological markers in older people at risk of mobility limitations. , 2014, Current pharmaceutical design.

[38]  I. Castan-Laurell,et al.  Effect of endurance training on skeletal muscle myokine expression in obese men: identification of apelin as a novel myokine , 2014, International Journal of Obesity.

[39]  L. Panton,et al.  Interrelationship among muscle, fat, and bone: Connecting the dots on cellular, hormonal, and whole body levels , 2014, Ageing Research Reviews.

[40]  Sungeun Kim,et al.  Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans. , 2014, The Journal of clinical endocrinology and metabolism.

[41]  M. Siervo,et al.  Osteosarcopenic obesity: the role of bone, muscle, and fat on health , 2014, Journal of cachexia, sarcopenia and muscle.

[42]  D. Annibali,et al.  Molecular and cell-based therapies for muscle degenerations: a road under construction , 2014, Front. Physiol..

[43]  Suhuan Liu,et al.  Association of Serum Irisin with Metabolic Syndrome in Obese Chinese Adults , 2014, PloS one.

[44]  A. Stengel,et al.  Irisin as a muscle-derived hormone stimulating thermogenesis – A critical update , 2014, Peptides.

[45]  Maren S Fragala,et al.  An Evidence-Based Comparison of Operational Criteria for the Presence of Sarcopenia , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[46]  Maren S Fragala,et al.  Criteria for Clinically Relevant Weakness and Low Lean Mass and Their Longitudinal Association With Incident Mobility Impairment and Mortality: The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[47]  G. Lynch,et al.  Elevated expression of activins promotes muscle wasting and cachexia , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  A. Datta-Mannan,et al.  Inhibition of activin A ameliorates skeletal muscle injury and rescues contractile properties by inducing efficient remodeling in female mice. , 2014, The American journal of pathology.

[49]  Maren S Fragala,et al.  The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[50]  An-Lin Cheng,et al.  Skeletal Muscle Troponin as a Novel Biomarker to Enhance Assessment of the Impact of Strength Training on Fall Prevention in the Older Adults , 2014, Nursing research.

[51]  Y. Mori,et al.  ROLE of exercise in maintaining the integrity of the neuromuscular junction , 2014, Muscle & nerve.

[52]  C. Still,et al.  Does IRISIN Have a BRITE Future as a Therapeutic Agent in Humans? , 2014, Current Obesity Reports.

[53]  C. Mantzoros,et al.  Irisin in humans: recent advances and questions for future research. , 2014, Metabolism: clinical and experimental.

[54]  N. Inestrosa,et al.  Wnt Signaling in Skeletal Muscle Dynamics: Myogenesis, Neuromuscular Synapse and Fibrosis , 2014, Molecular Neurobiology.

[55]  G. Lippi,et al.  Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers , 2014, Critical reviews in clinical laboratory sciences.

[56]  N. LeBrasseur,et al.  Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review , 2014, Gerontology.

[57]  Yuan Zhang,et al.  Irisin Stimulates Browning of White Adipocytes Through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signaling , 2014, Diabetes.

[58]  Yong-ri Jin,et al.  Regulation of the Follistatin Gene by RSPO-LGR4 Signaling via Activation of the WNT/β-Catenin Pathway in Skeletal Myogenesis , 2013, Molecular and Cellular Biology.

[59]  S. Brachat,et al.  An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy , 2013, Molecular and Cellular Biology.

[60]  N. Perrimon,et al.  The influence of skeletal muscle on systemic aging and lifespan , 2013, Aging cell.

[61]  M. Cesari,et al.  Proinflammatory cytokines, aging, and age-related diseases. , 2013, Journal of the American Medical Directors Association.

[62]  Mary T. Brinkoetter,et al.  Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. , 2013, European journal of endocrinology.

[63]  H. Heuft,et al.  Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients , 2013, PloS one.

[64]  P. Bourin,et al.  Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role? , 2013, Stem cells translational medicine.

[65]  L. Larsson,et al.  The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass , 2013, The Journal of cell biology.

[66]  C. Farina,et al.  Autocrine and immune cell‐derived BDNF in human skeletal muscle: implications for myogenesis and tissue regeneration , 2013, The Journal of pathology.

[67]  M. Cesari,et al.  Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. , 2013, The international journal of biochemistry & cell biology.

[68]  H. Erickson.  Irisin and FNDC5 in retrospect , 2013, Adipocyte.

[69]  P. Chase,et al.  Nuclear tropomyosin and troponin in striated muscle: new roles in a new locale? , 2013, Journal of Muscle Research and Cell Motility.

[70]  N. Binkley,et al.  What’s in a name revisited: should osteoporosis and sarcopenia be considered components of “dysmobility syndrome?” , 2013, Osteoporosis International.

[71]  O. Cappellari,et al.  Pericytes in Development and Pathology of Skeletal Muscle , 2013, Circulation research.

[72]  B. Pedersen.  Muscle as a secretory organ. , 2013, Comprehensive Physiology.

[73]  Jian-jun Liu,et al.  Lower circulating irisin is associated with type 2 diabetes mellitus. , 2013, Journal of diabetes and its complications.

[74]  J. Eckel,et al.  Adipo-Myokines: Two Sides of the Same Coin—Mediators of Inflammation and Mediators of Exercise , 2013, Mediators of inflammation.

[75]  R. Honkanen,et al.  Relationship between postmenopausal osteoporosis and the components of clinical sarcopenia. , 2013, Maturitas.

[76]  N. Khaper,et al.  The IL-6 Paradox: Context Dependent Interplay of SOCS3 and AMPK. , 2013, Journal of diabetes & metabolism.

[77]  J. Eckel,et al.  Regulation of follistatin-like protein 1 expression and secretion in primary human skeletal muscle cells , 2013, Archives of physiology and biochemistry.

[78]  F. Casanueva,et al.  FNDC5/Irisin Is Not Only a Myokine but Also an Adipokine , 2013, PloS one.

[79]  M. Polkey,et al.  Sustained Elevation of Circulating Growth and Differentiation Factor-15 and a Dynamic Imbalance in Mediators of Muscle Homeostasis Are Associated With the Development of Acute Muscle Wasting Following Cardiac Surgery* , 2013, Critical care medicine.

[80]  L. Al-Shaar,et al.  Gender differences in the heritability of musculoskeletal and body composition parameters in mother-daughter and mother-son pairs. , 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[81]  U. Wisløff,et al.  Evidence against a Beneficial Effect of Irisin in Humans , 2013, PloS one.

[82]  J. Moreno-Navarrete,et al.  Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. , 2013, The Journal of clinical endocrinology and metabolism.

[83]  M. Muscaritoli,et al.  Sarcopenia in critically ill patients: the new pandemia. , 2013, Minerva anestesiologica.

[84]  P. Dahinden,et al.  Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients , 2013, Experimental Gerontology.

[85]  W. Uter,et al.  C-terminal Agrin Fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction , 2013, Experimental Gerontology.

[86]  A. Lucia,et al.  Genes, physical fitness and ageing , 2013, Ageing Research Reviews.

[87]  H. Sell,et al.  Adaptive immunity in obesity and insulin resistance , 2012, Nature Reviews Endocrinology.

[88]  Mary T. Brinkoetter,et al.  FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. , 2012, Metabolism: clinical and experimental.

[89]  I. Dimauro,et al.  Acute exercise modulates BDNF and pro-BDNF protein content in immune cells. , 2012, Medicine and science in sports and exercise.

[90]  J. Wells,et al.  Sarcopenic obesity: A Critical appraisal of the current evidence. , 2012, Clinical nutrition.

[91]  T. Spector,et al.  Association of FTO gene variants with body composition in UK twins , 2012, Annals of human genetics.

[92]  A. Hadj Sassi,et al.  Overexpression of caveolin-3-enhanced protein synthesis rather than proteolysis inhibition in C2C12 myoblasts: relationship with myostatin activity , 2012, Journal of Physiology and Biochemistry.

[93]  James M. Allen,et al.  Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin , 2012, The Journal of cell biology.

[94]  M. Ruegg,et al.  Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases. , 2012, Current opinion in pharmacology.

[95]  B. Pedersen,et al.  Plasma and Muscle Myostatin in Relation to Type 2 Diabetes , 2012, PloS one.

[96]  S. Jaffrey,et al.  Intra-axonal Translation of SMAD1/5/8 Mediates Retrograde Regulation of Trigeminal Ganglia Subtype Specification , 2012, Neuron.

[97]  M. Febbraio,et al.  Muscles, exercise and obesity: skeletal muscle as a secretory organ , 2012, Nature Reviews Endocrinology.

[98]  P. Knaus,et al.  BMPs are mediators in tissue crosstalk of the regenerating musculoskeletal system , 2012, Cell and Tissue Research.

[99]  C. Jacobi,et al.  TAK-1/p38/nNFκB signaling inhibits myoblast differentiation by increasing levels of Activin A , 2012, Skeletal Muscle.

[100]  R. Iniesta,et al.  Sarcopenia in the elderly: diagnosis, physiopathology and treatment. , 2012, Maturitas.

[101]  J. Eckel,et al.  Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways , 2012, Diabetologia.

[102]  B. Spiegelman,et al.  A PGC1α-dependent myokine that drives browning of white fat and thermogenesis , 2012, Nature.

[103]  I. Bautmans,et al.  Chronic low-grade inflammation and age-related sarcopenia , 2012, Current opinion in clinical nutrition and metabolic care.

[104]  S. Brooks,et al.  Transforming growth factor‐beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin‐1 and scleraxis , 2012, Muscle & nerve.

[105]  D. Claflin,et al.  Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases , 2011, Nature Medicine.

[106]  F. López‐Soriano,et al.  Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance , 2011, Journal of cachexia, sarcopenia and muscle.

[107]  D. Allen,et al.  Expression and function of myostatin in obesity, diabetes, and exercise adaptation. , 2011, Medicine and science in sports and exercise.

[108]  M. Bolliger,et al.  Destabilization of the neuromuscular junction by proteolytic cleavage of agrin results in precocious sarcopenia , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  Tetsuo Kobayashi,et al.  Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis. , 2011, The American journal of pathology.

[110]  I. Janssen.  The epidemiology of sarcopenia. , 2011, Clinics in geriatric medicine.

[111]  R. S. Moraes,et al.  Inspiratory muscle training in type 2 diabetes with inspiratory muscle weakness. , 2011, Medicine and science in sports and exercise.

[112]  T. Redpath,et al.  Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.

[113]  J. Molkentin,et al.  Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. , 2011, American journal of physiology. Heart and circulatory physiology.

[114]  Yu-fei Li,et al.  Sarcopenia , 2011 .

[115]  C. Farina,et al.  Human Neurotrophin Receptor p75NTR Defines Differentiation-Oriented Skeletal Muscle Precursor Cells: Implications for Muscle Regeneration , 2011, Journal of neuropathology and experimental neurology.

[116]  Tzu-Feng Wang,et al.  Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway , 2011, Brain, Behavior, and Immunity.

[117]  Andrew E. Firth,et al.  Identification of evolutionarily conserved non-AUG-initiated N-terminal extensions in human coding sequences , 2011, Nucleic acids research.

[118]  H. Grönberg,et al.  Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15): a new marker of all‐cause mortality , 2010, Aging cell.

[119]  M. Francolini,et al.  Specific proteolytic cleavage of agrin regulates maturation of the neuromuscular junction , 2010, Journal of Cell Science.

[120]  A. Echaniz-Laguna,et al.  Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments. , 2010, Current drug targets.

[121]  Marcus D. Goncalves,et al.  Akt Deficiency Attenuates Muscle Size and Function but Not the Response to ActRIIB Inhibition , 2010, PloS one.

[122]  A. Grinberg,et al.  A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. , 2010, Endocrinology.

[123]  M. Kuhn,et al.  Postnatal PPARδ Activation and Myostatin Inhibition Exert Distinct yet Complimentary Effects on the Metabolic Profile of Obese Insulin-Resistant Mice , 2010, PloS one.

[124]  J. Baeyens,et al.  Sarcopenia: European consensus on definition and diagnosis , 2010, Age and ageing.

[125]  C. Drevon,et al.  IL-7 is expressed and secreted by human skeletal muscle cells. , 2010, American journal of physiology. Cell physiology.

[126]  S. B. Pedersen,et al.  Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: a 12-week randomized intervention study. , 2010, American journal of physiology. Endocrinology and metabolism.

[127]  G. A. Kan.  Epidemiology and consequences of sarcopenia. , 2009 .

[128]  K. Wollert,et al.  Growth-differentiation factor-15 in heart failure. , 2009, Heart failure clinics.

[129]  P. Cawthon,et al.  Sarcopenia: etiology, clinical consequences, intervention, and assessment , 2009, Osteoporosis International.

[130]  N. Bresolin,et al.  The low-affinity receptor for neurotrophins p75NTR plays a key role for satellite cell function in muscle repair acting via RhoA. , 2009, Molecular biology of the cell.

[131]  K. Tsuchida,et al.  Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. , 2009, American journal of physiology. Endocrinology and metabolism.

[132]  S. Hatakeyama,et al.  Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. , 2009, American journal of physiology. Cell physiology.

[133]  M. Febbraio,et al.  Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase , 2009, Diabetologia.

[134]  D. Hittel,et al.  Increased Secretion and Expression of Myostatin in Skeletal Muscle From Extremely Obese Women , 2009, Diabetes.

[135]  L. Ferrucci,et al.  Sarcopenic obesity: definition, cause and consequences , 2008, Current opinion in clinical nutrition and metabolic care.

[136]  N. Sims,et al.  Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. , 2008, Seminars in cell & developmental biology.

[137]  I. Conboy,et al.  Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells , 2008, Nature.

[138]  B. Pedersen,et al.  Skeletal muscle as an immunogenic organ. , 2008, Current opinion in pharmacology.

[139]  A. Rossi,et al.  Sarcopenic obesity: a new category of obesity in the elderly. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[140]  A. Russell,et al.  Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. , 2008, Rejuvenation research.

[141]  K. Tsuchida,et al.  Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[142]  Se-Jin Lee,et al.  Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways , 2007, PloS one.

[143]  M. Gleeson,et al.  Immune function in sport and exercise. , 2007, Journal of applied physiology.

[144]  B. Pedersen,et al.  Beneficial health effects of exercise--the role of IL-6 as a myokine. , 2007, Trends in pharmacological sciences.

[145]  A. Oberg,et al.  Does Reduced Skeletal Loading Account for Age‐Related Bone Loss? , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[146]  F. Haddad,et al.  Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. , 2006, Journal of applied physiology.

[147]  T. Hewett,et al.  GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein Activation , 2006, Circulation research.

[148]  M. Matzuk,et al.  Regulation of muscle growth by multiple ligands signaling through activin type II receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[149]  S. Bortoluzzi,et al.  Computational reconstruction of the human skeletal muscle secretome , 2005, Proteins.

[150]  T. Kumar.  Too many follistatins: racing inside and getting out of the cell. , 2005, Endocrinology.

[151]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[152]  T. Khurana,et al.  Myostatin propeptide‐mediated amelioration of dystrophic pathophysiology , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[153]  Se-Jin Lee.  Regulation of muscle mass by myostatin. , 2004, Annual review of cell and developmental biology.

[154]  W. N. Pappano,et al.  Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[155]  S. Bandinelli,et al.  Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. , 2003, American journal of physiology. Endocrinology and metabolism.

[156]  S. Kritchevsky,et al.  Strength and Muscle Quality in a Well‐Functioning Cohort of Older Adults: The Health, Aging and Body Composition Study , 2003, Journal of the American Geriatrics Society.

[157]  Denise M O'Hara,et al.  Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. , 2003, Biochemical and biophysical research communications.

[158]  B. Langley,et al.  Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression* , 2002, The Journal of Biological Chemistry.

[159]  R. Hewick,et al.  The Myostatin Propeptide and the Follistatin-related Gene Are Inhibitory Binding Proteins of Myostatin in Normal Serum* , 2002, The Journal of Biological Chemistry.

[160]  J. Argilés,et al.  Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. , 2002, Experimental cell research.

[161]  S. Welle,et al.  Insulin-like growth factor-1 and myostatin mRNA expression in muscle: comparison between 62–77 and 21–31yr old men , 2002, Experimental Gerontology.

[162]  C. Pichard,et al.  Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years , 2001, European Journal of Clinical Nutrition.

[163]  Se-Jin Lee,et al.  Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[164]  Ronenn Roubenoff,et al.  From the Chicago MeetingsSarcopenia , 2001 .

[165]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[166]  C. Franceschi,et al.  Inflamm‐aging: An Evolutionary Perspective on Immunosenescence , 2000 .

[167]  R. Roubenoff,et al.  Sarcopenic Obesity: Does Muscle Loss Cause Fat Gain?: Lessons from Rheumatoid Arthritis and Osteoarthritis a , 2000 .

[168]  A. Roberts,et al.  Autocrine secretion of TGF-β1 and TGF-β2 by pre-adipocytes and adipocytes: A potent negative regulator of adipocyte differentiation and proliferation of mammary carcinoma cells , 1998, In Vitro Cellular & Developmental Biology - Animal.

[169]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[170]  Se-Jin Lee,et al.  Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.

[171]  M. Sporn,et al.  Secretion and transcriptional regulation of transforming growth factor-beta 3 during myogenesis , 1991, Molecular and cellular biology.

[172]  J. Massagué,et al.  Type beta transforming growth factor is an inhibitor of myogenic differentiation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[173]  J. Liu.  Irisin as an exercise-stimulated hormone binding crosstalk between organs. , 2015, European review for medical and pharmacological sciences.

[174]  Y. Liu,et al.  Adiponectin action in skeletal muscle. , 2014, Best practice & research. Clinical endocrinology & metabolism.

[175]  L. Ferrucci,et al.  The impact of sarcopenia on a physical activity intervention: The lifestyle interventions and independence for elders pilot study (LIFE-P) , 2013, The journal of nutrition, health & aging.

[176]  Timothy J Doherty,et al.  Sarcopenia: prevalence, mechanisms, and functional consequences. , 2010, Interdisciplinary topics in gerontology.

[177]  S. Ross,et al.  How the Smads regulate transcription. , 2008, The international journal of biochemistry & cell biology.

[178]  C. Fischer.  Interleukin-6 in acute exercise and training: what is the biological relevance? , 2006, Exercise immunology review.

[179]  Mary L Bouxsein,et al.  Mechanisms of Disease: is osteoporosis the obesity of bone? , 2006, Nature Clinical Practice Rheumatology.

[180]  K. Yarasheski,et al.  Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. , 2002, The journal of nutrition, health & aging.

[181]  I. H. Rosenberg,et al.  Summary comments : Epidemiological and methodological problem in determining nutritional status of older persons , 1989 .